Table 1 Patient characteristics included in the study and of the patients who declined to participate
|  | Participants (n = 28) | Non-participants (n = 6) |
|---|---|---|
Age, years | ||
 Mean (SD) | 59.4 (8.2) | 60.7 (12.7) |
Sex (n, %) | ||
 Male | 18 (64) | 4 (67) |
 Female | 10 (36) | 2 (33) |
BMI, kg/m2 | ||
 Mean (SD) | 25.0 (3.6) | 25.6 (2.7) |
BMI, kg/m2 (n, %) | ||
 BMI < 20 | 1 (4) | 0 (0) |
 BMI 20–25 | 15 (53) | 2 (33) |
 BMI 25–30 | 7 (25) | 4 (67) |
 BMI > 30 | 5 (18) | 0 (0) |
HCT-CI (n, %) | ||
 0 | 13 (46) | 4 (67) |
 1–2 | 9 (32) | 2 (33) |
  ≥ 3 | 6 (21) | 0 (0) |
ECOG performance status (n, %) | ||
 0 | 6 (21) | 1 (17) |
 1 | 13 (46) | 4 (67) |
 2 | 9 (32) | 1 (17) |
Diagnosis (n, %) | ||
 MM | 16 (57) | 5 (83) |
 AML | 6 (21) | 0 (0) |
 ALL | 2 (7) | 0 (0) |
 Amyloidosis | 2 (7) | 0 (0) |
 MCL | 1 (4) | 0 (0) |
 MDS | 1 (4) | 0 (0) |
 Primary myelofibrosis | 0 (0) | 1 (17) |
Treatment history | ||
 Bortezomib- or IMID-based induction | 18 (64) | 5 (83) |
 Intensive chemotherapy (DA or HD ARA-C) | 7 (25) | 0 (0) |
 Rituximab-Bendamustine | 1 (4) | 0 (0) |
 Azacitidine | 1 (4) | 0 (0) |
 Methotrexate (ALL maintenance) | 1 (4) | 0 (0) |
 Ruxolitinib | 0 (0) | 1 (17) |
HSCT type (n, %) | ||
 Autologous | 19 (68) | 5 (83) |
 Allogeneic | 9 (32) | 1 (17) |